Company news

Ligand Pharmaceuticals Incorporated news in 2024

Ligand Pharmaceuticals Incorporated's news releases, calls and decks from 2024, newest first.

View company

Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance

December 9, 2024

Ligand to Present at Stifel 2024 Healthcare Conference

November 13, 2024

Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance

November 6, 2024

Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston

October 31, 2024

Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024

October 22, 2024

Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer

October 16, 2024

Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy

September 5, 2024

Ligand to Present at H.C. Wainwright 26th Annual Global Investment Conference

August 19, 2024

Ligand Reports Second Quarter 2024 Financial Results

August 5, 2024

Ligand to Report Second Quarter 2024 Financial Results on August 6, 2024

July 22, 2024

Ligand to Acquire APEIRON Biologics AG for $100 Million

July 7, 2024

Ligand Partner Verona Pharma Announces FDA Approval of Ohtuvayre™ (ensifentrine), First Inhaled Novel Mechanism for Maintenance Treatment of COPD in More Than 20 Years

June 26, 2024

Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Adults

June 17, 2024

Ligand to Participate in Upcoming Investor Conferences

May 22, 2024

Ligand Reports First Quarter 2024 Financial Results

May 6, 2024

Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement

May 6, 2024

Ligand to Report First Quarter 2024 Financial Results on May 7, 2024

April 22, 2024

Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference

April 7, 2024

Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™

April 2, 2024

Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference

March 4, 2024

Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 3, 2024

Ligand Reports Fourth Quarter and Full Year 2023 Financial Results

February 26, 2024

Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa®

February 21, 2024

Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires

February 15, 2024

Ligand to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024

February 12, 2024

U.S. Food and Drug Administration Approves ZELSUVMI™ as a First-in-Class Medication for the Treatment of Molluscum Contagiosum

January 4, 2024

Calls in 2024

Decks in 2024